MOR

MorphoSys AG (MOR) | Rumor.io

MorphoSys

MOR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 10

$MOR's token price increasing leads to more daily inference, with 100 tokens potentially generating $1-$3 of inference per day.
The higher $MOR's token price goes, the more API credits can be earned, with potential applications in powering AI agents.
$MOR is seen as a strong performer in the AI sector, with some users comparing it to $VVV and noting its potential for growth.

Generated by AI

Sentiment

Of the messages about MOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.91% +35.25
Bearish	—	—	—	6.09% -35.25

Bullish· May 8

The market capitalization of $MOR has increased to 50k MC, providing a solid foundation for growth.
The project's potential for unlimited growth and high liquidity make it an attractive investment opportunity.
The project's fair launch and transparent approach, including no snipers and proper selling and buying practices, demonstrate a commitment to community support and a positive user experience.

Bearish· Feb 6

MorphoSys's decision to sell Tafasitamab to Incyte for $25M may be a strategic move to keep Novartis from bidding on the drug.
The deal between MorphoSys and Novartis is likely to fall through, with Novartis potentially walking away with a small breakup fee.
MorphoSys's strategic mismanagement, including a failure to explore antibody-drug conjugates (ADCs), has led to significant losses for shareholders.

Generated by AI

Topics

Of the messages about MOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	3.25%
Announcements	—	—	—	31.71%
Controversies	—	—	—	0%
Earnings	—	—	—	45.53%
Macro	—	—	—	8.13%
Technical Analysis	—	—	—	11.38%

Analysts· Jun 3

SVB Leerink analyst Geoffrey Porges upgraded MorphoSys from Market Perform to Outperform.
Bryan Garnier analyst Victor Floc'h downgraded MorphoSys from Buy to Neutral.
Deutsche Bank set a price target of EUR 116 for MorphoSys, representing an 84% increase.

Announcements· Feb 7

MorphoSys AG (MOR) will be acquired by Novartis for €2.7B, with a cash offer of €68.00 per share, representing a 94% premium to the 1-month VWAP.
The deal is expected to close in the first half of 2024, subject to a 65% minimum acceptance threshold, and includes the sale of tafasitamab rights to Incyte for $25M.
Wells Fargo has reiterated an Overweight Rating for MorphoSys AG (MOR), with Novartis's acquisition of the company seen as a positive development for its cancer drugs.

Macro· Mar 19

China's debt problems may be addressed by improving governance and performance of state-owned enterprises (SOEs) or introducing mixed ownership reform (MOR).
State-owned enterprises account for a significant share of China's debt, output, employment, and strategic sectors, but face issues such as low profitability, high leverage, and corruption.
Introducing MOR could bring private or foreign capital, technology, and management expertise to SOEs, potentially improving their performance and China's overall economic situation.

Generated by AI

Community

Of the messages about MOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	23.89%
Newcomers	—	—	100%	76.11%

Regulars· Feb 7

The merger agreement between MorphoSys and Novartis has been disclosed, with the deal expected to close in the first half of 2024.
The FDA meeting's primary endpoint, SVR35, was met with a statistically significant result, but the secondary endpoint, TSS, was not, raising questions about the NDA filing.
MorphoSys's Pelabresib has shown good science and impressive results, particularly in spleen reduction and anemia benefit, making it a promising drug with KOLs' support.

Newcomers· Feb 7

The MorphoSys AG ($MOR) deal with Novartis ($NVS) involves a termination fee of €100M euro, which may make it difficult for $NVS to walk away from the agreement easily.
German takeover laws are more stringent than US laws, making it challenging for $MOR to back out of the deal, and a pre-NDA meeting between the two companies has been declined by $MOR.
New investors are researching $MOR and its bootstrapping timeline, with some considering buying the stock on its launch after a 91-day waiting period, while others are holding onto their shares despite a potential drop in price.

Generated by AI

News

VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer,

2mo agoUSA Today

Also Discussed

Investors talking about MOR also mention

#	Name	Attention
1	Galapagos NV American Depositary ReceiptGLPG	0%0
2	Valvoline Inc.VVV	0%0
3	I-Mab Sponsored ADRIMAB	0%0
4	Franklin Emerging Market Core Dividend Tilt Index ETFDIEM	0.01%new
5	Incyte Corp.INCY	0%new
6	INZY - Inozyme Pharma, Inc.	——
7	SGEN - Seagen Inc.	——
8	argenx SE American Depositary ReceiptARGX	0%0
9	MRTX - Mirati Therapeutics, Inc.	——
10	BeethovenX sFTMXSFTMX	0%new

MorphoSys AG

Location

Social

What share of all stock conversation is about MOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 10

$MOR's token price increasing leads to more daily inference, with 100 tokens potentially generating $1-$3 of inference per day.
The higher $MOR's token price goes, the more API credits can be earned, with potential applications in powering AI agents.
$MOR is seen as a strong performer in the AI sector, with some users comparing it to $VVV and noting its potential for growth.

Generated by AI

Sentiment

Of the messages about MOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	93.91% +35.25
Bearish	—	—	—	6.09% -35.25

Bullish· May 8

The market capitalization of $MOR has increased to 50k MC, providing a solid foundation for growth.
The project's potential for unlimited growth and high liquidity make it an attractive investment opportunity.
The project's fair launch and transparent approach, including no snipers and proper selling and buying practices, demonstrate a commitment to community support and a positive user experience.

Bearish· Feb 6

MorphoSys's decision to sell Tafasitamab to Incyte for $25M may be a strategic move to keep Novartis from bidding on the drug.
The deal between MorphoSys and Novartis is likely to fall through, with Novartis potentially walking away with a small breakup fee.
MorphoSys's strategic mismanagement, including a failure to explore antibody-drug conjugates (ADCs), has led to significant losses for shareholders.

Generated by AI

Topics

Of the messages about MOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	3.25%
Announcements	—	—	—	31.71%
Controversies	—	—	—	0%
Earnings	—	—	—	45.53%
Macro	—	—	—	8.13%
Technical Analysis	—	—	—	11.38%

Analysts· Jun 3

SVB Leerink analyst Geoffrey Porges upgraded MorphoSys from Market Perform to Outperform.
Bryan Garnier analyst Victor Floc'h downgraded MorphoSys from Buy to Neutral.
Deutsche Bank set a price target of EUR 116 for MorphoSys, representing an 84% increase.

Announcements· Feb 7

MorphoSys AG (MOR) will be acquired by Novartis for €2.7B, with a cash offer of €68.00 per share, representing a 94% premium to the 1-month VWAP.
The deal is expected to close in the first half of 2024, subject to a 65% minimum acceptance threshold, and includes the sale of tafasitamab rights to Incyte for $25M.
Wells Fargo has reiterated an Overweight Rating for MorphoSys AG (MOR), with Novartis's acquisition of the company seen as a positive development for its cancer drugs.

Macro· Mar 19

China's debt problems may be addressed by improving governance and performance of state-owned enterprises (SOEs) or introducing mixed ownership reform (MOR).
State-owned enterprises account for a significant share of China's debt, output, employment, and strategic sectors, but face issues such as low profitability, high leverage, and corruption.
Introducing MOR could bring private or foreign capital, technology, and management expertise to SOEs, potentially improving their performance and China's overall economic situation.

Generated by AI

Community

Of the messages about MOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	23.89%
Newcomers	—	—	100%	76.11%

Regulars· Feb 7

The merger agreement between MorphoSys and Novartis has been disclosed, with the deal expected to close in the first half of 2024.
The FDA meeting's primary endpoint, SVR35, was met with a statistically significant result, but the secondary endpoint, TSS, was not, raising questions about the NDA filing.
MorphoSys's Pelabresib has shown good science and impressive results, particularly in spleen reduction and anemia benefit, making it a promising drug with KOLs' support.

Newcomers· Feb 7

The MorphoSys AG ($MOR) deal with Novartis ($NVS) involves a termination fee of €100M euro, which may make it difficult for $NVS to walk away from the agreement easily.
German takeover laws are more stringent than US laws, making it challenging for $MOR to back out of the deal, and a pre-NDA meeting between the two companies has been declined by $MOR.
New investors are researching $MOR and its bootstrapping timeline, with some considering buying the stock on its launch after a 91-day waiting period, while others are holding onto their shares despite a potential drop in price.

Generated by AI

MorphoSys

Social

May 10

Bullish· May 8

Bearish· Feb 6

Analysts· Jun 3

Announcements· Feb 7

Macro· Mar 19

Regulars· Feb 7

Newcomers· Feb 7

VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

Also Discussed

MorphoSys AG

Company Information

Location

VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

Also Discussed

Social

May 10

Bullish· May 8

Bearish· Feb 6

Analysts· Jun 3

Announcements· Feb 7

Macro· Mar 19

Regulars· Feb 7

Newcomers· Feb 7